- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05699187
Face Transplantation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with severe facial disfigurement referred or self-identified to the MGH Face Transplantation Program will undergo a consultation with the PI (Dr. Cetrulo) who will perform a thorough clinical assessment and explain in detail the treatment protocol, risks and benefits of the face allotransplantation procedure and alternative options. At the time of appointment, candidates will be first requested to sign a face transplant Research Informed Consent form . Following the signing of these documents, the candidate will meet with the MGH Transplant Center team (see below for description of entire team), a clinical pharmacist, dietician, and a transplant social worker.
Appropriate subjects will then undergo further evaluation/medical screening procedures to determine their candidacy for face transplantation. Prospective recipients who are selected based on results of screening procedures will be invited to review and sign the full informed consent form prior to being wait-listed for the procedure.
There is a significant evaluation using tests, procedures, consults, and evaluations that will be performed as part of the standard of care for those clinically-approved for organ transplantation.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Curt Cetrulo, MD, FACS, FAAP
- Phone Number: 877-424-5678
- Email: CCETRULO@mgh.harvard.edu
Study Contact Backup
- Name: Curt Cetrulo, MD, FACS, FAAP
- Email: CCETRULO@mgh.harvard.edu
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Recent (≥6 months) or remote (i.e., several decades) severe facial disfigurement and/or facial functional impairment covering at least 25% of face and/or a major part e.g. nose, lips and desiring face transplantation.
- Aged 18-65 years. Noted should be that the maximal age difference between donor and recipient will be 10 years.
- Completion of the protocol informed consent form.
- No co-existing medical condition which, in the opinion of the study team, could affect the immunomodulatory protocol, surgical procedure, or functional results (see Donor and Recipient Exclusion Criteria below. If the condition is amenable to treatment, the study team must agree that said condition should not significantly enhance the surgical risks of facial transplantation.)
- No co-existing psycho-social problems (i.e., alcoholism, drug abuse).
- Negative for malignancy for past 5 years.
- Negative for HIV at transplant.
- Negative crossmatch with donor.
- If female of child-bearing potential, negative serum pregnancy test. If female of child-bearing potential, consent to use reliable contraception for at least one year following transplantation.
- Patient agrees to comply with the protocol and states a dedication to the immunomodulatory treatment regimen.
- No smoking for 6 months prior to transplant, as confirmed by blood testing.
Exclusion Criteria:
- Positive for any of the following conditions: Untreated sepsis, HIV (active or seropositive), active tuberculosis, hepatitis B or C (HCV Ab+ and HCV RNA+ (HCV Ab+ but RNA negative is acceptable), HBVcAb+, HBVsAg+ or viral DNA+), viral encephalitis, toxoplasmosis, malignancy (within past 5 years), current/recent (within months of donation/consent) IV drug abuse, paralysis of ischemic or traumatic origin, inherited peripheral neuropathy, infectious, post infectious, or inflammatory (axonal or demyelinating) neuropathy, toxic neuropathy (i.e. heavy metal poisoning, drug toxicity, industrial agent exposure), mixed connective tissue disease, severe deforming rheumatoid or osteoarthritis in the limb.
- Conditions that, in the opinion of the study team, may impact the immunomodulatory protocol potentially exposing the recipient to an unacceptable risk under immunosuppressive treatment, including all liver and renal disease.
- Sensitized recipients with high levels (>=50%) of panel-reactive HLA antibodies.
- Conditions that may impact the success of the surgical procedure or increase the risk of postoperative complications including inherited coagulopathies like Hemophilia, Von-Willebrand's disease, Protein C and S deficiency, Thrombocythemias, Thalassemias, Sickle Cell disease, etc.
- Mixed connective tissue diseases and collagen diseases can result in poor wound healing after surgery.
- Conditions that may impact functional outcomes including lipopolysaccharidosis and amyloidosis (may impact nerve regeneration) or rare disorders of bone healing like osteopetrosis.
- Pregnant, breastfeeding or planning to become pregnant within the next 2 years.
- Unable or unwilling to use an acceptable birth control method for 2 years following transplant. The patient cannot have given birth in the past 2 years. We acknowledge that a female recipient of childbearing age must carefully consider the associated risks of the transplant and immunosuppression and personally prioritize these issues and the lead face transplant surgeon (Dr. Cetrulo) will implement this subject in the preoperative education of the patient during consultation.
- Patients will be required to stop smoking for 6 months prior to listing and abstain from postoperative smoking
- If a subject does not receive a transplant after one year of enrollment, clinical consent will be re-obtained from that subject and clinical consent will be re-obtained yearly while the subject is enrolled and waiting for a donor.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Face Transplant Recipient
The procedure will be carried out simultaneously by two teams of transplant surgeons for each face transplanted in the operation.
The teams will be divided between the functions of tissue recovery (donor operation) and transplant surgery (recipient operation).
In most cases the facial graft will include the entire nose; the soft tissues of the mid-face, including all its blood vessels, muscles, and nerves; and a significant portion of the mid-facial skeleton.
|
Facial allotransplantation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of motor function of face
Time Frame: 1 Year
|
Function of face as assessed by ability to move face, smile, frown, etc.
|
1 Year
|
Incidence of intact sensation of face
Time Frame: 1 Year
|
Sensation of face intact using standard methods (sharp vs dull, presence of numbness)
|
1 Year
|
Incidence of an ascetically satisfactory appearing face
Time Frame: 1 Year
|
Evaluated by overall appearance, symmetry
|
1 Year
|
Incidence of a cost benefit to facial transplant
Time Frame: 1 Year
|
This will be assessed by standard treatment of facial disfigured patients vs face transplant
|
1 Year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of rejection episodes on triple therapy immunosuppression
Time Frame: 1 Year
|
1 Year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Curt Cetrulo, MD, FACS, FAAP, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021P002531
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Facial Injuries
-
University of UtahCompletedSynkinesis | Facial Asymmetry | Facial Nerve Injuries | Facial Paresis Associated With Facial Nerve Dysfunction
-
Johns Hopkins UniversityRecruitingFacial Injuries | Facial Deformity | Craniofacial Defects | Craniofacial Injuries | Traumatic Wounds and Injuries | Facial TransplantationUnited States
-
NYU Langone HealthRecruitingFacial Injuries | Hand Injuries | Facial Deformity | Craniofacial Injuries | Upper Extremity Injuries | Face InjuriesUnited States
-
University of MichiganRecruitingFacial DefectUnited States
-
University of Texas at AustinCompletedFacial LacerationUnited States
-
David Grant U.S. Air Force Medical CenterWithdrawnFacial Injuries and Disorders
-
Xinhua Hospital, Shanghai Jiao Tong University...UnknownInjury of Facial Nerve, Unspecified Side, Initial Encounter
-
University of PittsburghUnited States Department of DefenseCompletedFacial Injuries | Adipose TissueUnited States
-
Children's Hospitals and Clinics of MinnesotaWithdrawnFacial and Scalp LacerationsUnited States
-
Recep Tayyip Erdogan UniversityActive, not recruitingLaser Therapy | Methylprednisolone | Nerve Injury | Facial Nerve InjuriesTurkey
Clinical Trials on Face allotransplantation
-
Assistance Publique Hopitaux De MarseilleUnknown
-
Second Affiliated Hospital, School of Medicine,...Zhejiang University; Sir Run Run Shaw Hospital; Xijing Hospital, Air Force Medical...RecruitingKidney Transplant Rejection | Skin GraftChina
-
Methodist Health SystemCompleted
-
Centre Hospitalier Universitaire, AmiensRecruiting
-
Brigham and Women's HospitalRecruitingLimb Amputation | Extremity AmputationUnited States
-
Lawson Health Research InstituteLondon Health Sciences CentreWithdrawn
-
NYU Langone HealthRecruitingFacial Injuries | Hand Injuries | Facial Deformity | Craniofacial Injuries | Upper Extremity Injuries | Face InjuriesUnited States
-
Andalusian School of Public HealthCompleted
-
Kayseri City HospitalTC Erciyes UniversityNot yet recruitingLearning | Exercise Test